Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new study shows that an important drug used in the treatment of malignant melanoma has little effect on the melanoma cells themselves. Instead, it activates immune-system cells to fight the disease.
Subscribe to our email newsletter
The drug, called interferon alpha (IFNa), is used to clean up microscopic tumor cells that may remain in the body following surgery for the disease. It is the only drug approved for this purpose.
Researchers say that these findings underscore the need to develop ways to make melanoma cells more vulnerable to the drug, or to overcome the block within the cells that prevents them from responding to it.
The study showed that melanoma cells taken directly from patients, as well as those grown in the laboratory, respond poorly to IFNa, even when the drug is given at very high doses, while immune cells respond well to the same substance. The study, led by researchers with the Ohio State University Comprehensive Cancer Center, is published in the journal Clinical Cancer Research.
“IFNa is effective in only 10 to 20% of patients, but it’s the best therapy available for these patients, and no therapies on the horizon have been proven any more effective,” says principal investigator William Carson III, professor of surgery and a melanoma specialist at Ohio State’s James Cancer Hospital and Solove Research Institute.
“It is critical that we understand exactly how this drug works and learn how to improve its effectiveness.”
IFNa is an immune-system hormone made by the body to help other immune cells recognize and destroy developing tumors. As a drug, the substance is used to treat melanoma and other cancers.